Synlait Milk Launches Three-Stage Turnaround After $80.6M Loss and $472M Debt Pile

Synlait unveils three-horizon recovery strategy after challenging half-year

Synlait Milk has outlined a structured “Stabilise, Simplify, Scale” roadmap to guide its recovery following a difficult HY26 result. The dairy processor reported a Total Group EBITDA loss of ($34.7M) and Total Group NPAT of ($80.6M) for the six months ended 31 January 2026, with net debt climbing to $472.1M. Operating cash flow during the period was ($183.4M), whilst Total Group Revenue came in at $949.0M.

The Synlait Milk HY26 Recovery Roadmap (ASX: SM1) represents a phased turnaround approach designed to restore operational stability, strengthen financial resilience, and position the business for future growth. Management has withdrawn FY26 financial guidance, signalling that execution of the recovery roadmap takes priority over short-term forecasting.

The three-horizon framework breaks down as follows: Stabilise focuses on delivering operational stability that meets customer expectations and builds greater optionality; Simplify aims to align priorities, sharpen capability, and grow high-margin products from existing assets to lift profitability; Scale is designed to expand markets, channels, and customers whilst executing future growth opportunities.

What caused the HY26 result?

Synlait identified five sequential challenges that compounded to create what management described as a “perfect storm” during HY26:

1. Inventory shortfall stemming from manufacturing challenges in the second half of FY25 created a need to rebuild customer inventory.
2. Manufacturing plan adjustment enabled focus on catch-up production but disrupted normal operations.
3. Tactical milk sales became necessary when the revised plan resulted in surplus milk, particularly during peak season.
4. Pivoting under pressure occurred when milk sales did not go to plan, forcing teams to pause catch-up production and process unsold milk. Dryer configurations limited production to whole milk powder (WMP).
5. Global downturn in WMP pricing saw prices decrease sharply at the end of calendar year 2025, resulting in unfavourable Ingredients returns.

These challenges hit Synlait’s two largest segments hardest. Ingredients gross profit fell 89% year-on-year, whilst Advanced Nutrition gross profit dropped 87%. The company noted that an insurance claim is expected to recover a portion of the losses relating to the FY25 manufacturing challenges.

What is a recovery roadmap in corporate turnarounds?

A recovery roadmap in a corporate turnaround context refers to a phased strategic framework designed to guide a company from operational distress back to sustainable performance. The “Stabilise, Simplify, Scale” approach is a widely recognised turnaround methodology.

Stabilise means stopping operational deterioration and restoring basic business functions. This typically involves addressing immediate quality issues, rebuilding customer confidence, and securing financial flexibility. For Synlait, this includes implementing company-wide quality controls (the Synlait Care programme) and tightening regulatory compliance, particularly for the Chinese market.

Simplify involves focusing resources on core activities and exiting non-core or loss-making operations. Companies in this phase typically streamline their asset base, reduce complexity, and sharpen their strategic focus. Synlait’s North Island asset sale exemplifies this stage.

Scale represents the growth phase, where the company leverages its stabilised operations and simplified structure to pursue expansion. This includes entering new markets, developing new products, and deepening customer relationships from a leaner operational base.

Companies use this phased approach because attempting to grow whilst operations remain unstable often deepens losses. The sequential nature ensures each foundation is solid before building the next layer.

North Island sale nears completion

The sale of Synlait’s North Island assets to global healthcare leader Abbott for approximately NZ$307 million is expected to complete on 1 April 2026. This transaction represents the most material near-term catalyst in Synlait’s recovery timeline.

The North Island operations recorded an EBITDA loss of ($2.7M) during HY26. Whilst this performance improved compared to prior periods due to the assets being used in the rebuild of customer inventory, losses have persisted. The divestment will remove a drag on Synlait’s operational performance and strengthen the balance sheet through debt reduction.

Transitional service agreements will support the handover, and Synlait has agreed with Abbott that base powder production will remain available to Synlait post-completion. Management described the outcome as creating a “smaller, simpler, and stronger Synlait” with an expected future profitability uplift.

The closure of Synlait’s Palmerston North office in line with the single-site focus in Canterbury is expected to generate a benefit of over $2 million per year. Combined with the North Island sale proceeds, the transaction materially improves Synlait’s financial resilience and simplifies the equity story for investors.

Bright spots in Consumer and Foodservice

Whilst Ingredients and Advanced Nutrition segments faced significant headwinds, Synlait’s Consumer and Foodservice units delivered positive momentum during HY26.

Consumer segment highlights:

• Revenue up 51% driven by Dairyworks growth and commodity price increases
• Gross profit up 22%
• Growth in export markets across retail and wholesale channels
• New private label contracts boosting butter volumes
• Increased fresh milk and cream margins due to timing of commodities and contracted pricing

Foodservice segment highlights:

• Revenue up 48% as traction in overseas markets continues to build for UHT cream
• Margin swung from negative to positive, driven by improved pricing with key customers and softening fat prices
• UHT volumes up 24%
• China office expanded, with Shanghai team grown to nine staff members
• Second generation whipping cream successfully launched, with all China volume now transitioned

The Foodservice division held a major presence at the China International Import Expo, with 70 New Zealand farmers attending. This generated strong in-market interest and strengthened brand positioning. Management indicated the business is preparing to double UHT cream volumes in FY27.

Banking covenants and liquidity position

Synlait’s banking syndicate, comprising ANZ Bank, China Construction Bank, Bank of China, Rabobank, Industrial Commercial Bank of China, HSBC, Bank of Communications, and Bank of East Asia, agreed to covenant amendments post-balance date.

The amendments provide breathing room during the recovery period:

• Interest cover ratio covenant waived for the 31 January 2026 reporting date
• Interest cover ratio adjusted to 0.25x for reporting dates falling on 30 April 2026 and 31 July 2026
• Net senior debt to EBITDA ratio suspended for 31 July 2026
• Working capital ratio unchanged at 1.35x for the period from 1 August to 31 March and 1.5x from 1 April to 31 July

Total banking facilities stand at $400M. Synlait also holds a $130M shareholder loan from Bright Dairy International Investment Limited, maturing 12 July 2026. Bright Dairy has preliminarily indicated its future shareholder support, subject to relevant approvals. This indication reduces refinancing risk as the maturity date approaches.

Net debt of $472.1M is $80.2M higher than the prior year, mainly due to operational performance. Bank debt will reduce following the North Island sale’s completion, although management acknowledged “more work to do” on deleveraging.

What’s next for Synlait?

Synlait has outlined six operational priorities under its recovery roadmap, collectively known as the “Big 6”:

• Operational Stability: Quality and operational deliverables aligned to tightening global regulatory and compliance standards, particularly in China
• Quality Performance: New Quality Strategy and Food Safety and Quality Policy delivered, with company-wide quality commitment (Synlait Care) implemented
• Customer Satisfaction: Bigger, Better, Faster project to improve customer journey, with business development team strengthened
• Financial Resilience: Focus on balance sheet strength and liquidity management
• Financial Performance: Cost discipline and margin improvement across all segments
• Strengthening Culture: High performance culture framework and company values (Synlait Spirit) launched, shifting culture from reactive to proactive

The forecast FY26 milk price is $9.90/kgMS total, comprising a base milk price of $9.50, average Synlait milk incentive of $0.30, and Synlait Secured Milk Premium of $0.10. Canterbury milk supply is 3% ahead of the prior year as at 31 January 2025.

Near-term milestones for investors to monitor:

• 1 April 2026: Expected completion of North Island sale to Abbott
• Ongoing FY26: Continued progress on US FDA review for a2 infant formula submission
• FY27 planning: Expansion of Foodservice volumes in China and Southeast Asia, with internal targets to potentially double UHT cream volumes
• Mid-2026: Covenant testing dates (30 April and 31 July) and shareholder loan maturity (12 July)

The company’s strategic shift towards a customer-centric business culture includes readying the business to onboard and serve a more diversified customer base. New products are in development utilising existing assets, whilst the broader Revenue team has been right-sized to customer opportunities.

Don’t Miss the Next Consumer Staples Breakout

Join 20,000+ investors receiving FREE ASX breaking news within minutes of release, complete with in-depth analysis. Get market-moving alerts from Big News Blast delivered straight to your inbox the moment news breaks. Click the “Free Alerts” button to stay ahead on Consumer Staples coverage.